Cutaneous JAK Expression in Vitiligo.
Amira Ali Abdel MotalebYasmin M TawfikMohamed A El-MokhtarSherouk ElkadyAmira F El-GazzarSuzan Kamel- ElSayedSara M AwadPublished in: Journal of cutaneous medicine and surgery (2020)
JAK1 and more prominently JAK3 are upregulated in vitiliginous skin and possibly contribute to the pathogenesis of the disease. Accordingly, selective JAK3/1 inhibition may provide a favorable therapeutic opportunity for vitiligo patients.This study is registered on the ClinicalTrials.gov Identifier: NCT03185312.